Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of AMG 330 continuous intravenous infusion in myeloid malignancies
NL-OMON55859Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2016
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of eluvixtamab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Amgen. Primary endpoints: Safety and tolerability and Maximum tolerated dose / biologically active dose. Started Feb 2016; status: active, not recruiting.
02
Drugs
eluvixtamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55859.